BRIAN KENNEDY: Open Payments
NPI 1952958837 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$352 in 14 payments from 8 companies in 2025. Trend: 2023 $913 · 2024 $945 · 2025 $352
Food & beverage: $352
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $199 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Lilly USA, LLC | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| ABBVIE INC. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
Products named: Ozempic, Rybelsus, TRELEGY ELLIPTA, MOUNJARO, PAXLOVID, CAPLYTA, VRAYLAR, AIRSUPRA.
Industry payments across AZ — which companies pay providers there.
